Biotech IPO's Analyzed

"Since the fall of 2003, 33 young biotechnology and specialty pharma companies have entered the public domain. Together, they embody the new generation of drug discovery and development firms, whose fledgling product candidates could ultimately become breakthrough therapies for everything from ocular diseases to psychiatric disorders. But do these newer drug candidates - or the technologies used to create them -- differ from those already on the market or under development by more mature firms? And if so, how?"

From about.com